Virological response to darunavir in patients infected with HIV is linked to darunavir resistance-associated mutations corrected by the count of mutations with positive impact and is not associated with pharmacological and combined virological/pharmacological parameters

Fundamental and Clinical Pharmacology

Volumn 26, Issue 4, 2012, Pages 538-542

  Dailly, Eric ^a,b   Rodallec, Audrey ^a,c   Allavena, Clotilde ^a,c   Deslandes, Guillaume ^a   Garnier, Elisabeth ^a,c   Billaud, Eric ^a,c   Ferré, Virginie ^a,c   Reliquet, Véronique ^a,c   Bouquié, Régis ^a,b   Raffi, François ^a,c   Jolliet, Pascale ^a,b  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b Universite de Nantes   (France)

^c UNIVERSITÉ DE NANTES   (France)

Author keywords

Darunavir; Genotypic inhibitory quotient; Human immunodeficiency virus

Indexed keywords

DARUNAVIR; DARUNAVIR PLUS RITONAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; FEMALE; GENOTYPIC INHIBITORY QUOTIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PHARMACOLOGICAL PARAMETERS; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

ADOLESCENT; ADULT; AGED; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; RETROSPECTIVE STUDIES; RNA, VIRAL; SULFONAMIDES; VIRAL LOAD; YOUNG ADULT;

EID: 84863550558     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2011.00949.x     Document Type: Article

References (10)

1. McKeage K., Perry C.M., Keam S.J. Darunavir: a review of its use in the management of HIV infection in adults. Drugs (2009) 69 477-503.
2. La Porte C. Inhibitory quotient in HIV pharmacology. Curr. Opin. HIV AIDS (2008) 3 283-287.
3. Moltó J., Santos J.R., Pérez-Alvarez N. et al. Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients. Antimicrob. Agents Chemother. (2008) 52 3928-3932.
4. Pellegrin I., Wittkop L., Joubert L.M. et al. Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study). Antivir. Ther. (2008) 13 271-279.
5. Delaugerre C., Buyck J.F., Peytavin G. et al. Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study). J. Clin. Virol. (2010) 47 248-252.
6. De Meyer S., Descamps D., Van Baelen B. et al. Confirmation of the negative impact of protease mutations I47V, I54M, T74P and I84V and the positive impact of protease mutation V82A on virological response to darunavir/ritonavir. 17th International HIV drug resistance workshop: basic principles and clinical implications. 9-13 June 2009, Fort Myers, Florida, USA. Abstract 126.
7. Descamps D., Lambert-Niclot S., Marcelin A.G. et al. Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients. J. Antimicrob. Chemother. (2009) 63 585-592.
8. Martin J., Deslandes G., Dailly E. et al. A liquid chromatography-tandem mass spectrometry assay for quantification of nevirapine, indinavir, atazanavir, amprenavir, saquinavir, ritonavir, lopinavir, efavirenz, tipranavir, darunavir and maraviroc in the plasma of patients infected with HIV. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. (2009) 877 3072-3082.
9. Sekar V., De Paepa E., Van Baelen B. et al. Pharmacokinetic/pharmacodynamic (PK/PD) analyses of darunavir in the TITAN study. 11th European AIDS conference, 24-27 October 2007, Madrid, Spain. Abstract P4.1/10.
10. de Meyer S., Vangeneugden T., van Baelen B. et al. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res. Hum. Retroviruses (2008) 24 379-388.